Yi Lin

Yi Lin is a hematologist-oncologist at Mayo Clinic specializing in CAR-T cell therapy and bispecific antibodies for multiple myeloma. She has been a key clinical investigator in trials of ciltacabtagene autoleucel (cilta-cel) and teclistamab for heavily pretreated myeloma. Her research focuses on understanding immune effector mechanisms in myeloma, optimizing patient selection for cellular therapies, and managing toxicities of CAR-T and bispecific antibodies. She has contributed to FDA-approved indications for novel myeloma immunotherapies.